Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
A phase I trial of ISIS 3521 (IS1641A), an antisense inhibitor of protein kinase C alpha, combined with carboplatin and paclitaxel in patients with cancer. Yuen, A., Sikic, B. I., Advani, R., Fisher, G., Halsey, J., Lum, B., Geary, R., Kwoh, T. J., Holmlund, J. T., Dorr, A. AMER ASSOC CANCER RESEARCH. 1999: 3846S–3847S
View details for Web of Science ID 000083945700577